Workvivo by Zoom is named preferred migration partner for Workplace from Meta

Meta is discontinuing Workplace and will partner with Workvivo to assist with customer transitions.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, Workvivo by Zoom was named Meta’s only preferred migration partner for its customers as it retires Workplace from Meta.

Meta is discontinuing Workplace from Meta – its employee engagement platform. To assist with customer transitions, Meta will partner with Workvivo as its only preferred migration partner.

Workplace from Meta and Workvivo plan to provide migration tools for customers migrating to Workvivo and Workvivo will also offer additional implementation services at no further cost to support customers’ transition.

Workplace from Meta customers can find more information about migrating to Workvivo here.

John Goulding, CEO and founder of Workvivo, said: “We know that the news today may be disruptive for Workplace from Meta customers, but we’re so excited about the opportunity to support and help them. Meta has made a huge impact in this market, and we believe that Workvivo is the natural choice for Workplace from Meta customers to transition their employee experience platform.

“It’s our top priority to support customers through this transition, and our team is working to make this process as frictionless as possible. We put our customers first, and this will be no different for the Workplace from Meta customers. We are excited to welcome Workplace from Meta customers into our incredible customer community and see the amazing things they can do with Workvivo.”

Eric S. Yuan, CEO and founder of Zoom said: “Since Workvivo joined the Zoom family, we’ve seen how powerful this platform is at engaging workforces and bringing culture to life – especially for frontline employees who may not have a desk or even an email address. Workvivo has seen momentous growth as organizations around the world are increasingly prioritizing the employee experience. We are excited to support Workplace from Meta’s customers and help them reach their goals of reaching and engaging employees – whether they’re desk or frontline workers.”

Workvivo by Zoom is the employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work.

Acquired by Zoom in 2023, Workvivo extends the Zoom Workplace platform to offer its customers new ways to keep employees informed, engaged, and connected. Workvivo is working with some of the world’s best-known brands to help them boost employee engagement and bring their culture to life digitally, including Dollar General, the Virgin Group, Bupa, Ryanair, Lululemon and Amazon.

About Workvivo by Zoom

Workvivo is an employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work. The platform unifies employee communications, engagement, intranet, and measurement features into one modern employee app that captures the heartbeat of the organization and brings its culture to life.

Founded in 2017, Workvivo has seen momentous growth, which led to its acquisition by Zoom in 2023. Workvivo powers the employee experience at companies all over the world across all industries, including Amazon, Motherson, White Castle, Bupa and Ryanair. Workvivo regularly tops software review sites, including Gartner Digital, with a #1 spot on G2 for internal communications, intranet and engagement tool categories. For more information, visit www.workvivo.com.

Public Relations
Eleanor O’Mahony
[email protected]

GlobeNewswire Distribution ID 9117415

En pleine transformation stratégique, le King Faisal Specialist Hospital and Research Centre accueille un nouveau directeur général adjoint

RIYAD, Arabie saoudite, 14 mai 2024 (GLOBE NEWSWIRE) — L’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre a récemment accueilli le Dr Björn Zoéga en tant que directeur général adjoint. Cette nomination souligne son engagement en faveur de la promotion et du maintien de l’excellence en matière de santé. Le Dr Zoéga, réputé pour sa vaste expérience en gestion et sa maîtrise des politiques de la santé, rejoint une équipe dédiée à l’heure où l’hôpital continue de piloter des initiatives stratégiques clés.

Le KFSH&RC, leader de la recherche médicale et des services cliniques, continue d’attirer des ressources expertes à l’échelle mondiale pour renforcer sa mission d’excellence en matière de santé. L’arrivée du Dr Zoéga fait avancer la stratégie de transformation numérique de l’hôpital, conçue pour doper son efficacité opérationnelle et améliorer les soins prodigués aux patients. Son expertise dans la promotion de collaborations internationales, comme en témoigne son ancien rôle de président de l’Alliance des hôpitaux universitaires européens (ou « EUHA » pour European University Hospital Alliance) et sa participation à des initiatives telles que JOIN4ATMP, visant à promouvoir l’accès à des thérapies innovantes, concourent à un meilleur alignement des services du KFSH&RC sur les tendances mondiales en matière de santé.

Les projets clés de l’hôpital prévoient le déploiement de technologies numériques avancées pour standardiser les mécanismes propres aux soins prodigués aux patients, l’adoption de nouveaux modèles de soins et la modernisation de ses installations. Ces efforts stratégiques visent à améliorer l’accès aux services médicaux et à induire une meilleure communication à leur propos, et traduisent l’engagement du KFSH&RC envers l’établissement de nouvelles normes en matière de santé.

Les précédentes contributions du Dr Zoéga à l’hôpital universitaire Karolinska, placé au deuxième rang européen et au septième rang mondial du classement 2024 des meilleurs hôpitaux du monde établi par Newsweek, ont joué en faveur d’une culture d’apprentissage continu et de collaboration entre les professionnels de santé. Elles répondent ainsi parfaitement aux objectifs du KFSH&RC. Son rôle dans la promotion de programmes comme EUCARE et sa participation au développement des échanges intra Europe d’infirmières en soins intensifs en période de crise a considérablement renforcé le développement du personnel et appuyé l’objectif de son précédent hôpital d’attirer les meilleurs talents ; un principe reflété dans le parcours de transformation du KFSH&RC. Maintenant que le Dr Zoéga prend part au leadership du KFSH&RC, l’établissement s’apprête à renforcer son rôle d’acteur clé dans le façonnage de la santé de demain en Arabie saoudite.

À propos du King Faisal Specialist Hospital and Research Centre :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen-Orient, en se voyant décerner, pour la deuxième année consécutive, le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen-Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen-Orient en 2024.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre — que Dieu le préserve — pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

King Faisal Specialist Hospital and Research Centre Dá as Boas-Vindas ao Novo CEO Interino Durante Suas Transformações Estratégicas

RIADE, Arábia Saudita, May 14, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) nomeou recentemente o Dr. Björn Zoéga como CEO Interino, confirmando o seu empenho em promover e incentivar a excelência no cuidado da saúde. O Dr. Zoéga, conhecido por sua vasta experiência em gestão e políticas de saúde, se une a uma equipe dedicada em um momento em que o hospital continua a impulsionar iniciativas estratégicas importantes.

O KFSH&RC, líder em pesquisa médica e serviços clínicos, continua a atrair experiência global para reforçar sua visão de excelência em saúde. Com o envolvimento do Dr. Zoéga, o hospital dá seguimento à sua estratégia de transformação digital que visa aprimorar a eficiência operacional e aperfeiçoar o atendimento ao paciente. Sua experiência na promoção de colaborações internacionais, evidenciada no seu antigo cargo de presidente da European University Hospital Alliance (EUHA) e com as iniciativas como a Join4ATMP, que visa promover o acesso a terapias inovadoras, alinha ainda mais os serviços do KFSH&RC às tendências globais de saúde.

Os principais projetos do KFSH&RC incluem a implantação de tecnologias digitais avançadas para agilizar o processo de atendimento ao paciente, adoção de modelos de atendimento inovadores e atualização das instalações. Esses esforços estratégicos visam aumentar o acesso aos serviços médicos e facilitar uma melhor comunicação, refletindo a dedicação do KFSH&RC em estabelecer novos padrões de saúde.

As contribuições anteriores do Dr. Zoéga no Karolinska University Hospital, que é o segundo melhor da Europa e o sétimo do mundo de acordo com o 2024 World’s Best Hospitals da revista Newsweek, onde ele cultivou uma cultura de aprendizagem contínua e colaboração entre profissionais de saúde, alinham-se bem com os objetivos do KFSH&RC. O seu papel na promoção de programas como o EUCARE e na facilitação do intercâmbio de enfermeiros de cuidados intensivos em toda a Europa durante crises melhorou significativamente o desenvolvimento do pessoal e apoiou o objetivo do seu hospital anterior de atrair os melhores talentos – um princípio espelhado na jornada de transformação do KFSH&RC. Com o Dr. Zoéga contribuindo para a liderança, o KFSH&RC está pronto para promover seu papel como ator fundamental na formação do futuro dos cuidados de saúde na Arábia Saudita.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro-Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

Mitsumi Distribution spearheading Technological Advancement at GITEX Africa 2024.

DUBAI, UAE – African Media Agency – 14 May 2024 – Mitsumi Distribution, a leading IT, Telco, Value and AI distributor in the Middle East and Africa, proudly announces its participation in GITEX Africa 2024. With a widespread presence spanning 28 countries and strategic partnerships with over 27+ vendors, Mitsumi Distribution is poised to showcase front-line technological advancements and innovations at this esteemed event.

Mr. Mitesh Shah – Managing Director

Mitsumi’s focus at GITEX Africa 2024 revolves around the theme of “Pioneering Future Solutions Today.” Reflecting this commitment, Mitsumi will unveil an extensive array of pioneering technologies and innovative solutions that are reshaping the landscape of IT, Telco, AI, and value-driven solutions. In the realm of AI, Mitsumi will showcase advancements such as machine learning, generative AI, computer vision, and AI-driven chatbots, among others. In the Value Division section, emphasis will be placed on cloud solutions, security, infrastructure solutions, and more. Seasoned experts from Mitsumi, alongside key principals, will be on hand to provide insights and facilitate direct engagement with the latest industry innovations. The prestigious vendors showcased at Mitsumi’s booth are industry giants such as Acer, Array Networks, Asus, Canon, DellTechnologies, HPE, HP, Infinix, Lenovo, Lexar, Oppo, Samsung, Seagate, Techno, and VIVO.

We are thrilled to announce our participation in GITEX Africa 2024,” exclaimed Mr. Mitesh Shah, Managing Director at Mitsumi Distribution. “In this ever-evolving landscape of innovation, AI stands out as one of the most prominent topics, continually expanding its reach and impact. We are excited to seize this opportunity to unveil new partnerships and business plans, further propelling our commitment to driving technological advancement and empowering businesses across Middle East & Africa and showcasing our solutions from the top vendors”.

Visit Mitsumi Distribution at Stand 5B-20, Hall No.5, CLOUD X IOT X AI, from the 29th of May to the 31st of May 2024 to experience firsthand the advanced technologies and solutions shaping the future. Engage with Mitsumi’s team of experts, explore the latest projects and developments, and discover how Mitsumi can empower your organization to thrive in the digital age.

About Mitsumi Distribution

Mitsumi Distribution is a leading technology provider specializing in distribution channels in Africa, the Middle East and African French-speaking countries. With over two decades of experience, Mitsumi Distribution has firmly established itself as a trusted authority in the region. The company offers a wide range of innovative technology products & solutions, with a focus on IT, Telco, AI, cloud computing, networking, servers and storage. Mitsumi Distribution is committed to providing superior quality products, exceptional service and unparalleled value to its valued partners. www.mitsumidistribution.com

MedSource Labs Announces Innovation in Safety, Accuracy and Functionality of IV Catheters

MedSource Labs Unveils ClearSafe Comfort® and TrueSafe Comfort® Blood Control Safety IV Catheters to protect medical staff and patients

[Minneapolis, Minnesota, Chanhassen], May 14, 2024 (GLOBE NEWSWIRE) — MedSource Labs moves the needle in the peripheral safety IV market with the announcement of ClearSafe Comfort and TrueSafe Comfort Blood Control IV Catheters with groundbreaking active blood control check valve technology.

ClearSafe Comfort and TrueSafe Comfort Blood Control IV catheters provide significant benefits over other IV catheters.

  1. Safety: A new blood control device to significantly reduce the risk of exposure to bloodborne pathogens to the caregiver and patient.
  2. Precision: A translucent flashback chamber confirms vessel entry and ensures accuracy.
  3. Front-line functionality: The ergonomic design and non-slip grip ensure easy handling for healthcare workers.

 

“Healthcare professionals subject themselves to the risks associated with needlestick injuries and exposure to bloodborne pathogens every time they access a vein,” said Dave Kunelius, President at MedSource Labs. “ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters have been engineered to minimize these risks, allowing medical staff to better serve their patients without distraction or worry.”

These devices conform to the U.S. Needlestick Safety and Prevention Act.

MedSource Labs is a leading medical product developer and supplier specializing in high-quality products and innovative medical product development. The ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters are part of MedSource Labs’ high-performing IV catheter lines focused on caring for the caregiver. See the TrueSafe Animations and ClearSafe Animations for a detailed view.

“Quality has always been a key component of our IV catheter products, and the ClearSafe Comfort and TrueSafe Comfort blood control products raise the bar for medical staff safety and patient care,” said Kunelius.

MedSource Labs is ISO 13485:2016 certified for quality management in medical device manufacturing, registered with the FDA, and the blood control catheters are 510(k) Cleared Products.

ABOUT MEDSOURCE LABS

MedSource Labs is a leading provider of quality medical products, specializing in high-quality products, equipment and innovative class II medical product development. For over two decades, MedSource Labs has been a trusted provider of quality medical products at a superb value. Recently, MedSource Labs has expanded into new markets and grown its international services and offerings, including a focus on the EMERGE product imagine/design/build process.

Attachment

Jeremy Belloit
MedSource Labs
(952) 472-0131
[email protected]

GlobeNewswire Distribution ID 9116905

‫ميتسومي للتوزيع تقود التقدم التكنولوجي في معرض جيتكس أفريقيا 2024

دبي، الإمارات العربية المتحدة – 14 مايو 2024 – تعلن شركة ميتسومي للتوزيع، الشركة الرائدة في مجال توزيع تكنولوجيا المعلومات والاتصالات وعروض القيمة والذكاء الاصطناعي في الشرق الأوسط وإفريقيا، بفخر عن مشاركتها في معرض جيتكس أفريقيا 2024. ومع تواجد واسع النطاق يشمل 28 دولة فضلاً عن الشراكات الاستراتيجية مع أكثر من 27 بائعًا، تستعد شركة ميتسومي للتوزيع لعرض التطورات والابتكارات التكنولوجية المتقدمة في هذا الحدث المرموق.

يتمحور تركيز ميتسومي في معرض جيتكس أفريقيا 2024 حول موضوع “ريادة الحلول المستقبلية اليوم”. وتجسيدًا لهذا الالتزام، ستكشف ميتسومي النقاب عن مجموعة متنوعة من التقنيات الرائدة والحلول المبتكرة التي تعيد تشكيل مشهد تكنولوجيا المعلومات، والاتصالات، والذكاء الاصطناعي، والحلول القائمة على القيمة. وفي مجال الذكاء الاصطناعي، ستعرض ميتسومي التطورات مثل تعلم الآلة، والذكاء الاصطناعي التوليدي، ورؤية الحاسوب، وروبوتات الدردشة التي تعتمد على الذكاء الاصطناعي، وغيرها. وفي قسم عروض القيمة، سيتم التركيز على الحلول السحابية والأمن وحلول البنية التحتية والمزيد. سيكون الخبراء المتمرسون من ميتسومي، جنبًا إلى جنب مع المديرين الرئيسيين، على استعداد لتقديم رؤى وتسهيل المشاركة المباشرة مع أحدث ابتكارات الصناعة. ويضم جناح ميتسومي عمالقة الصناعة من البائعين المرموقين مثل آيسر، وآيري نتوركس، وآسوس، وكانون، وديل تكنولوجيز، وإتش بي إي، وإتش بي، وإنفينيكس، وليكسار، وأوبو، وسامسونج، وسيجيت، وتكنو، وفيفو.

صرح السيد ميتيش شاه، المدير العام لشركة ميتسومي للتوزيع، قائلاً: “يسعدنا أن نعلن عن مشاركتنا في معرض جيتكس أفريقيا 2024”. “في هذا المشهد الابتكاري المتطور باستمرار، يبرز الذكاء الاصطناعي كواحد من أهم المواضيع، ويتوسع باستمرار في نطاقه وتأثيره. ونحن متحمسون لاغتنام هذه الفرصة للكشف عن شراكات وخطط عمل جديدة، وتعزيز التزامنا بقيادة التقدم التكنولوجي، وتمكين الشركات في جميع أنحاء الشرق الأوسط وأفريقيا، وعرض حلولنا من كبار البائعين.

تفضلوا بزيارة ميتسومي للتوزيع في الجناح 5B-20، القاعة رقم 5، السحابة × إنترنت الأشياء × الذكاء الاصطناعي (Stand 5B-20, Hall No.5, CLOUD X IOT X AI)، في الفترة من 29 مايو إلى 31 مايو 2024 للتجربة المباشرة للتقنيات والحلول المتقدمة التي تشكل المستقبل، وللتفاعل مع فريق خبراء ميتسومي، ولاستكشاف أحدث المشاريع والتطورات، ولاكتشاف كيف يمكن لشركة ميتسومي تمكين مؤسستكم من الازدهار في العصر الرقمي.

حول شركة ميتسومي للتوزيع:

ميتسومي للتوزيع هي شركة رائدة في مجال توفير التكنولوجيا المتخصصة في قنوات التوزيع في أفريقيا والشرق الأوسط والدول الأفريقية الناطقة بالفرنسية. رسخت شركة ميتسومي للتوزيع مكانتها بقوة كسلطة موثوقة في المنطقة بفضل ما لديها من أكثر من عقدين من الخبرة. تقدم الشركة مجموعة متنوعة من المنتجات والحلول التقنية المبتكرة، مع التركيز على تكنولوجيا المعلومات والاتصالات والذكاء الاصطناعي والحوسبة السحابية والشبكات والخوادم والتخزين، كما تلتزم شركة ميتسومي للتوزيع بتقديم منتجات فائقة الجودة وخدمة استثنائية وقيمة لا مثيل لها إلى شركائها الكرام. www.mitsumidistribution.com

للاستفسارات الإعلامية، يُرجى التواصل عبر البريد الإلكتروني:

[email protected]

Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024

Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q1 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
[email protected]

Attachment

GlobeNewswire Distribution ID 1000950583

FM meets Syrian counterpart on sidelines of Manama summit preparatory meetings


Deputy Prime Minister and Minister of Foreign Affairs and Expatriates, Ayman Safadi, met on Monday with Syrian Minister of Foreign Affairs and Expatriates, Faisal Mekdad, ahead of the Arab Foreign Ministers’ preparatory meeting for the Arab League Council at the summit level, which is hosted by the Kingdom of Bahrain.

The two ministers discussed efforts aimed at halting the Israeli aggression on the Gaza Strip and the humanitarian catastrophe caused by the aggression.

The two ministers also discussed the agenda of the Arab Foreign Ministers’ meeting and ways to enhance coordination and cooperation on priority issues, primarily the Palestinian issue, and the efforts exerted within the Arab context to achieve security and stability in the region.

Safadi and Mekdad touched on efforts to reach a political solution to the Syrian crisis that preserves the unity and cohesion of Syria, realizes the aspirations of its people, respects its sovereignty, rids it of terrorism and provides the necessary conditions for t
he voluntary return of Syrian refugees to their country.

They emphasized the importance of the role of the Arab Ministerial Contact Group on Syria within the efforts made in the context of the Arab track.

Safadi underscored the need to reach a political solution to the Syrian crisis according to a step-by-step methodology in line with UN Security Council Resolution 2254, which addresses all the humanitarian, security and political repercussions of the crisis.

Safadi and Mekdad also covered several bilateral issues, including border security and the fight against drug smuggling, and reviewed the results of the contacts conducted by the concerned authorities in the two countries to stop smuggling operations and defeat the danger they pose.

The two ministers underlined the continuation of consultation and coordination within the framework of the common interest of ending the Syrian crisis and developing cooperation that reflects positively on the two countries.

Source: Jordan News Agency